Rassekh S Rod, Rieder Michael, 't Jong Geert
Canadian Paediatric Society, Drug Therapy and Hazardous Substances Committee, Ottawa, Ontario, Canada.
Paediatr Child Health. 2023 Jun 6;28(4):205-251. doi: 10.1093/pch/pxad002. eCollection 2023 Jul.
The past two decades have seen enormous advancements in medical knowledge around the role of genetic factors of variability, both in human disease and drug response. This knowledge is increasingly being translated into guidelines that inform drug dosing, monitoring for efficacy and safety, and determining the suitability of specific agents to treat patients. Health Canada and the U.S. Food and Drug Administration have recommended using genetic information to guide dosing for more than 20 drugs. There are no current, comprehensive paediatric guidelines to assist health care professionals in the use of genetics to inform medication dosing, safety, and efficacy in children, and such guidance is urgently needed. This statement helps to guide clinician understanding of the role of pharmacogenetics and how to use this information when prescribing medications in paediatrics.
在过去二十年里，围绕人类疾病和药物反应中基因变异因素所起的作用，医学知识取得了巨大进展。这些知识越来越多地被转化为指导原则，用于指导药物剂量、疗效和安全性监测，以及确定特定药物治疗患者的适用性。加拿大卫生部和美国食品药品监督管理局已建议使用基因信息来指导20多种药物的剂量调整。目前尚无全面的儿科指南来帮助医疗保健专业人员利用遗传学知识指导儿童用药的剂量、安全性和疗效，而此类指导意见迫切需要。本声明有助于指导临床医生理解药物遗传学的作用，以及在儿科开处方时如何使用这些信息。
